Prelude Therapeutics Files Q1 2025 10-Q
Ticker: PRLD · Form: 10-Q · Filed: May 6, 2025 · CIK: 1678660
| Field | Detail |
|---|---|
| Company | Prelude Therapeutics Inc (PRLD) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
Prelude Therapeutics filed its Q1 2025 10-Q, showing updated financials and business operations.
AI Summary
Prelude Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business developments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and strategic direction of Prelude Therapeutics, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Prelude Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's annual accounting period.)
- 2025-03-31 — Period End Date (The specific date through which financial information is reported.)
- 2025-01-01 — Period Start Date (The beginning of the reporting period for this 10-Q.)
Key Players & Entities
- Prelude Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250506 (date) — Filing date
- 175 INNOVATION BOULEVARD, WILMINGTON, DE 19805 (address) — Company's business and mail address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed with the SEC on May 6, 2025.
What is Prelude Therapeutics Inc.'s fiscal year end?
Prelude Therapeutics Inc.'s fiscal year ends on December 31st.
What is the company's primary business address?
The company's business address is 175 INNOVATION BOULEVARD, WILMINGTON, DE 19805.
What is the SIC code for Prelude Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Prelude Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Prelude Therapeutics Inc (PRLD).